The Identification of Different Lung Diseases by Analysis of Volatile Organic Compounds in Breath Samples
PHNOSE
Application of Nanotechnology and Chemical Sensors for Lung Diseases by Respiratory Samples
1 other identifier
interventional
500
1 country
1
Brief Summary
The investigators assume that by analysis of different volatile organic compounds in the breath, using nanotechnology, the investigators will be able to identify a unique respiratory signature of different diseases including asthma, chronic obstructive pulmonary disease (COPD) and pulmonary hypertension.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable asthma
Started May 2012
Typical duration for not_applicable asthma
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2012
CompletedFirst Submitted
Initial submission to the registry
June 6, 2012
CompletedFirst Posted
Study publicly available on registry
June 29, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2015
CompletedJune 29, 2012
June 1, 2012
2.6 years
June 6, 2012
June 28, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Volatile organic compounds signature measured by mass spectrometer and electronic signal measured by the electronic nose, difference between the study groups at one and 12 months
up to 12 months
Study Arms (1)
lung disease
NO INTERVENTIONInterventions
Breath sample will be collected by a special nylon bag
Eligibility Criteria
You may qualify if:
- Diagnosis of asthma according to the American Thoracic Society guidelines.
- Diagnosis of chornic obstructive pulmonary disease according to the American Thoracic Society, guidelines.
- Diagnosis of pulmoanry hypertension according to the American Thoracic Society guidelins
- Age-18-85 year old
You may not qualify if:
- known carriers of infectious diseases: HIV, hepatitis B, C
- pregnancy
- History of lung cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Carmel Medical Center
Haifa, 34362, Israel
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Amer Ubaid
Carmel Medical Center
- PRINCIPAL INVESTIGATOR
Yochai Adir, PI
Carmel Medical Center
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 6, 2012
First Posted
June 29, 2012
Study Start
May 1, 2012
Primary Completion
December 1, 2014
Study Completion
June 1, 2015
Last Updated
June 29, 2012
Record last verified: 2012-06